Review of NICE Technology Appraisal Guidance No. 61; Capecitabine and tegafur uracil for metastatic colorectal cancer, and No. 176; Cetuximab for the first line treatment of metastatic colorectal cancer

The Institute was proposing that:

• There is no new evidence available for TA61 and it can therefore be incorporated into the on-going clinical guideline for the diagnosis and management of colorectal cancer that is due to be published in October 2011.
• TA176 should not be incorporated verbatim into the on-going clinical guideline as the results of the further subgroup analyses of the COIN study could potentially lead to the need to update the recommendations in the future. Therefore, we proposed it should instead be cross-referenced.

During consultation, the majority of comments received by the Institute agreed with the proposals put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposals.

May 2011